Increased Neutralization and IgG Epitope Identification After MVA-MERS-S Booster Vaccination Against Middle East Respiratory Syndrome
Overview
Authors
Affiliations
Vaccine development is essential for pandemic preparedness. We previously conducted a Phase 1 clinical trial of the vector vaccine candidate MVA-MERS-S against the Middle East respiratory syndrome coronavirus (MERS-CoV), expressing its full spike glycoprotein (MERS-CoV-S), as a homologous two-dose regimen (Days 0 and 28). Here, we evaluate the safety (primary objective) and immunogenicity (secondary and exploratory objectives: magnitude and characterization of vaccine-induced humoral responses) of a third vaccination with MVA-MERS-S in a subgroup of trial participants one year after primary immunization. MVA-MERS-S booster vaccination is safe and well-tolerated. Both binding and neutralizing anti-MERS-CoV antibody titers increase substantially in all participants and exceed maximum titers observed after primary immunization more than 10-fold. We identify four immunogenic IgG epitopes, located in the receptor-binding domain (RBD, n = 1) and the S2 subunit (n = 3) of MERS-CoV-S. The level of baseline anti-human coronavirus antibody titers does not impact the generation of anti-MERS-CoV antibody responses. Our data support the rationale of a booster vaccination with MVA-MERS-S and encourage further investigation in larger trials. Trial registration: Clinicaltrials.gov NCT03615911.
Generating MVA-Vector Vaccine Candidates and Testing Them in Animal Models.
Tscherne A, Meyer Zu Natrup C, Kalodimou G, Volz A Methods Mol Biol. 2024; 2860:297-340.
PMID: 39621276 DOI: 10.1007/978-1-0716-4160-6_20.
Weskamm L, Tarnow P, Harms C, Huchon M, Raadsen M, Friedrich M iScience. 2024; 27(8):110470.
PMID: 39148710 PMC: 11325358. DOI: 10.1016/j.isci.2024.110470.
Muller-Krauter H, Mezzacapo J, Kluver M, Baumgart S, Becker D, Fathi A Med Microbiol Immunol. 2024; 213(1):6.
PMID: 38722338 PMC: 11082005. DOI: 10.1007/s00430-024-00789-w.
Mayer L, Weskamm L, Fathi A, Kono M, Heidepriem J, Krahling V NPJ Vaccines. 2024; 9(1):20.
PMID: 38278816 PMC: 10817990. DOI: 10.1038/s41541-023-00801-z.
Kubinski M, Beicht J, Zdora I, Biermann J, Puff C, Gerlach T Front Immunol. 2023; 14:1182963.
PMID: 37153588 PMC: 10160477. DOI: 10.3389/fimmu.2023.1182963.